Completed EARLY_PHASE1 INTERVENTIONAL 2-arm NCT02824393

Experimental Autologous Mesenchymal Stem Cell Therapy in Treatment of Chronic Autoimmune Urticaria

Sponsor: Acıbadem Labcell

Conditions Autoimmune Diseases Immune System Diseases Skin Diseases Urticaria

Interventions Autologous mesenchymal stem cell

Updated 8 times since 2017 Last updated: Jul 17, 2018 Started: Mar 3, 2017 Primary completion: May 15, 2018 Completion: Jul 15, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A EARLY_PHASE1 clinical study on Autoimmune Diseases and Immune System Diseases, this trial is completed. The trial is conducted by Acıbadem Labcell and has accumulated 8 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed EARLY_PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed EARLY_PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed EARLY_PHASE1
Aug 2018 — Jan 2021 [monthly]

Completed EARLY_PHASE1

Status: Recruiting → Completed

▶ Show 3 earlier versions

Jun 2018 — Aug 2018 [monthly]

Recruiting EARLY_PHASE1
Jun 2017 — Jun 2018 [monthly]

Recruiting EARLY_PHASE1

Status: Not Yet Recruiting → Recruiting · Phase: PHASE1 → EARLY_PHASE1
Jan 2017 — Jun 2017 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Acıbadem Labcell
Celal Bayar University
The Scientific and Technological Research Council of Turkey

Data source: Celal Bayar University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Manisa, Turkey (Türkiye)